摘要
目的探讨安罗替尼联合调强适形放疗(IMRT)治疗无法手术的非小细胞肺癌(NSCLC)患者的疗效。方法根据治疗方法的不同将102例无法手术的NSCLC患者分为对照组和研究组,每组51例,对照组患者采取IMRT治疗,研究组患者采取安罗替尼联合IMRT治疗。随访18个月,比较两组患者的临床疗效、总生存率、无进展生存期(PFS)和总生存期(OS),比较不同病理类型对照组、研究组患者的肿瘤特异性生存率。结果研究组患者的客观缓解率高于对照组,差异有统计学意义(P﹤0.05)。治疗后6、12、18个月,研究组患者的总生存率均高于对照组,差异均有统计学意义(P﹤0.05)。治疗后6、12、18个月,不同病理类型对照组、研究组患者的肿瘤特异性生存率比较,差异均无统计学意义(P﹥0.05)。研究组患者的PFS和OS均明显长于对照组,差异均有统计学意义(P﹤0.01)。结论安罗替尼联合IMRT治疗无法手术的NSCLC患者可提高临床疗效和总生存率,延长患者的PFS和OS。
Objective To investigate the efficacy of anlotinib combined with intensity-modulated radiotherapy(IMRT)in the treatment of inoperable non-small cell lung cancer(NSCLC)patients.Method A total of 102 patients with inoperable NSCLC were divided into control group and study group according to different treatment methods,with 51 cases in each group.Patients in the control group were treated with IMRT,and patients in the study group were treated with anlotinib combined with IMRT.Followed up for 18 months,the clinical efficacy,overall survival rate,progressionfree survival(PFS)and overall survival(OS)of the two groups were compared,the tumor-specific survival rates of patients with different pathological type in control group and study group were also compared.Result The objective response rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).At 6,12 and 18 months after treatment,the overall survival rates of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).At 6,12 and 18 months after treatment,there were no significant differences in tumor-specific survival rates of patients with different pathological type in the control group and the study group(P>0.05).The PFS and OS in the study group were significantly longer than those in the control group,and the differences were statistically significant(P<0.01).Conclusion Anlotinib combined with IMRT in the treatement of patients with inoperable NSCLC can improve clinical efficacy and overall survival rate,and prolong patients’PFS and OS.
作者
王凯
史广超
陶中营
WANG Kai;SHI Guangchao;TAO Zhongying(Department of Respiratory and Critical Care Medicine,2Department of Oncology,Xuchang Central Hospital,Xuchang 461000,He’nan,China)
出处
《癌症进展》
2024年第8期850-853,共4页
Oncology Progress
基金
河南省医学科技攻关计划联合共建项目(LHGJ20191401)。
关键词
安罗替尼
调强适形放疗
非小细胞肺癌
疗效
anlotinib
intensity-modulated radiotherapy
non-small cell lung cancer
efficacy
